/ /

Ophthalmology Times Staff Reports
Vitrectomy for floaters can be safe, effective
Symptomatic floaters can be safely and effectively treated with vitrectomy using 25-gauge instruments, and without inducing posterior vitreous detachment or removing the anterior vitreous, said Christianne A. Wa, a third-year medical student at USC School of Medicine, Los Angeles.
Novel compounds help relieve dry eye
A novel investigational agent appears to help control uncomfortable symptoms of dry eye. The results of OPUS-I, a phase III randomized clinical trial, found that lifitegrast demonstrated superiority to placebo in reducing corneal fluorescein and conjunctival lissamine staining.
PEX associated with CVD, CVA in meta-analysis
Pseudoexfoliation syndrome (PEX) appears to be significantly associated with both cardiovascular (CVD) and cerebrovascular disease (CVA), according to a new meta-analysis, said Helen Chung, MD.
IVAN, GEFAL: Two anti-VEGFs ‘equivalent’
Ranibizumab and bevacizumab appear to be equally effective for the treatment age-related macular degeneration (AMD). The results of two large randomized multicenter trials—the IVAN and GEFAL—found that both drugs had similar effects on vision acuity and lesion morphology.
Glaucoma care costs rising, but moderately
The cost of caring for patients with glaucoma has risen in the past decade, but at a lower rate than that of general or medical inflation. For Medicare beneficiaries, the greatest expense was not the treatment for glaucoma per se, but rather for cataracts and retinal eye care, said Harry Quigley, MD.
Genetics factor in vitamin D, AMD link
Adequate levels of vitamin D can decrease the risk of age-related macular degeneration (AMD), but most markedly in individuals with two risk alleles for the CFH Y402H genotype, said Amy Millen, PhD.
High ER stress may contribute to POAG
Primary open-angle glaucoma is generally associated with elevations in IOP, and damage to the cells residing within the trabecular meshwork is most likely a contributing factor, said Markus H. Kuehn, PhD.
AREDS2 clarifies role of supplements for advanced AMD
The addition of the carotenoids, lutein and zeaxanthin, and the omega-3 fatty acids, DHA and EPA, to a supplement formulation does not further reduce the risk of disease progression in age-related macular degeneration (AMD), said Emily Y. Chew, MD.
Keynote series to feature three distinguished speakers
Three keynote speakers, including two Nobel laureates, will present lectures during the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) May 5 to 9 at the Washington State Convention Center. This year, the ARVO/Alcon Keynote Series will include Oliver Smithies, DPhil, Roger Tsien, PhD, and Christopher Murray, MD, DPhil.
Three special sessions among ARVO highlights
Attendees of the 2013 meeting of the Association for Research in Vision and Ophthalmology (ARVO) will want to make time for three special sessions at the Washington State Convention Center. These sessions include results from the Age-Related Eye Disease Study 2 (AREDS2), Inhibition of VEGF in Age-related Choroidal Neovascularisation 2 (IVAN2) Study, and Groupe d’Evaluation Français Avastin versus Lucentis (GEFAL) Study, as well as the National Eye Institute audacious goals initiative.


View Results